An Angiopoietin-like Protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis

Oncotarget

Volumn 6, Issue 15, 2015, Pages 13822-13834

  Carbone, Carmine ^a   Piro, Geny ^b   Fassan, Matteo ^a   Tamburrino, Anna ^a   Mina, Maria Mihaela ^b   Zanotto, Marco ^a   Chiao, Paul J ^d   Bassi, Claudio ^c,d   Scarpa, Aldo ^a,d   Tortora, Giampaolo ^b,d   Melisi, Davide ^a,d  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

ANGPTL2; EMT; LILRB2; Pancreatic cancer

Indexed keywords

ANGIOPOIETIN LIKE PROTEIN 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN; K RAS PROTEIN; LEUKOCYTE IMMUNOGLOBULIN LIKE RECEPTOR B2; PROTEIN P14; PROTEIN P16; RECEPTOR; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANGIOPOIETIN; ANGPTL2 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LILRB2 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ADULT; AGED; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; TISSUE SECTION; HEK293 CELL LINE; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETINS; AUTOCRINE COMMUNICATION; CARCINOGENESIS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HEK293 CELLS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION;

EID: 84931048137     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2635     Document Type: Article

References (28)

1. Melisi D and Budillon A. Pancreatic cancer: between bench and bedside Current drug targets. 2012; 13(6):729-730.
2. Melisi D, Calvetti L, Frizziero M and Tortora G. Pancreatic cancer: systemic combination therapies for a heterogeneous disease Current pharmaceutical design. 2014; 20(42):6660-6669.
3. Tamburrino A, Piro G, Carbone C, Tortora G and Melisi D. Mechanisms of resistance to chemotherapeutic and antiangiogenic drugs as novel targets for pancreatic cancer therapy. Frontiers in pharmacology. 2013; 4:56.
4. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H and Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages PLoS Med. 2010; 7(4):e1000267.
5. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Olah A, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial Jama. 2010; 304(10):1073-1081.
6. Iacobuzio-Donahue CA, Velculescu VE, Wolfgang CL and Hruban RH. Genetic basis of pancreas cancer development and progression: insights from whole-exome and wholegenome sequencing Clin Cancer Res. 2012; 18(16):4257-4265.
7. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, Hruban RH, Maitra A, Kinzler K, Vogelstein B and Goggins M. Presence of somatic mutations in most earlystage pancreatic intraepithelial neoplasia Gastroenterology. 2012; 142(4):730-733 e739.
8. Iacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project Gut. 2012; 61(7):1085-1094.
9. Yachida S and Iacobuzio-Donahue CA. Evolution and dynamics of pancreatic cancer progression Oncogene. 2013; 32(45):5253-5260.
10. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B and Iacobuzio-Donahue CA. Distant metastasis occurs late during the genetic evolution of pancreatic cancer Nature. 2010; 467(7319):1114-1117.
11. Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA and Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies Cell. 2012; 148(1-2):362-375.
12. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD and Stanger BZ. EMT and dissemination precede pancreatic tumor formation Cell. 2012; 148(1-2):349-361.
13. Tortora G, Melisi D and Ciardiello F. Angiogenesis: a target for cancer therapy Current pharmaceutical design. 2004; 10(1):11-26.
14. Kim I, Moon SO, Koh KN, Kim H, Uhm CS, Kwak HJ, Kim NG and Koh GY. Molecular cloning, expression, and characterization of angiopoietin-related protein angiopoietin-related protein induces endothelial cell sprouting. J Biol Chem. 1999; 274(37):26523-26528.
15. Tabata M, Kadomatsu T, Fukuhara S, Miyata K, Ito Y, Endo M, Urano T, Zhu HJ, Tsukano H, Tazume H, Kaikita K, Miyashita K, Iwawaki T, Shimabukuro M, Sakaguchi K, Ito T, et al. Angiopoietin-like protein 2 promotes chronic adipose tissue inflammation and obesity-related systemic insulin resistance Cell metabolism. 2009; 10(3):178-188.
16. Aoi J, Endo M, Kadomatsu T, Miyata K, Nakano M, Horiguchi H, Ogata A, Odagiri H, Yano M, Araki K, Jinnin M, Ito T, Hirakawa S, Ihn H and Oike Y. Angiopoietinlike protein 2 is an important facilitator of inflammatory carcinogenesis and metastasis Cancer Res. 2011; 71(24):7502-7512.
17. Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao P, Abbruzzese JL and Melisi D. Anti-VEGF Treatment Resistant Pancreatic Cancers Secrete Proinflammatory Factors that Contribute to Malignant Progression by Inducing an EMT cell phenotype. Clin Cancer Res. 2011.
18. Zheng J, Umikawa M, Cui C, Li J, Chen X, Zhang C, Huynh H, Kang X, Silvany R, Wan X, Ye J, Canto AP, Chen SH, Wang HY, Ward ES and Zhang CC. Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development Nature. 2012; 485(7400):656-660.
19. Chang Z, Ju H, Ling J, Zhuang Z, Li Z, Wang H, Fleming JB, Freeman JW, Yu D, Huang P and Chiao PJ. Cooperativity of oncogenic K-ras and downregulated p16/ INK4A in human pancreatic tumorigenesis PLoS One. 2014; 9(7):e101452.
20. Kalluri R and Weinberg RA. The basics of epithelialmesenchymal transition J Clin Invest. 2009; 119(6):1420-1428.
21. Aoi J, Endo M, Kadomatsu T, Miyata K, Ogata A, Horiguchi H, Odagiri H, Masuda T, Fukushima S, Jinnin M, Hirakawa S, Sawa T, Akaike T, Ihn H and Oike Y. Angiopoietin-like protein 2 accelerates carcinogenesis by activating chronic inflammation and oxidative stress Mol Cancer Res. 2014; 12(2):239-249.
22. Endo M, Nakano M, Kadomatsu T, Fukuhara S, Kuroda H, Mikami S, Hato T, Aoi J, Horiguchi H, Miyata K, Odagiri H, Masuda T, Harada M, Horio H, Hishima T, Nomori H, et al. Tumor cell-derived angiopoietin-like protein ANGPTL2 is a critical driver of metastasis Cancer Res. 2012; 72(7):1784-1794.
23. Odagiri H, Kadomatsu T, Endo M, Masuda T, Morioka MS, Fukuhara S, Miyamoto T, Kobayashi E, Miyata K, Aoi J, Horiguchi H, Nishimura N, Terada K, Yakushiji T, Manabe I, Mochizuki N, et al. The secreted protein ANGPTL2 promotes metastasis of osteosarcoma cells through integrin alpha5beta1, p38 MAPK, and matrix metalloproteinases Science signaling. 2014; 7(309):ra7.
24. Chang Z, Li Z, Wang X, Kang Y, Yuan Y, Niu J, Wang H, Chatterjee D, Fleming JB, Li M, Abbruzzese JL and Chiao PJ. Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells Clin Cancer Res. 2013; 19(3):549-559.
25. Melisi D, Ossovskaya V, Zhu C, Rosa R, Ling J, Dougherty PM, Sherman BM, Abbruzzese JL and Chiao PJ. Oral poly(ADP-ribose) polymerase-1 inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer, preventing acute neurotoxicity Clin Cancer Res. 2009; 15(20):6367-6377.
26. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method Methods. 2001; 25(4):402-408.
27. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, D'Armiento FP, Cionini L, Bianco AR, Tortora G, Ciardiello F and Bunn P. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model Mol Cancer Ther. 2004; 3(8):977-983.
28. Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A and Tortora G. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers Clin Cancer Res. 2011; 17(20):6531-6541.